Several clinical trials have demonstrated a considerable therapeutic advantage for the use of CDK4/6 inhibitors, like palbociclib, in the treatment of advanced breast cancer that is hormone receptor-positive but HER2-negative (Finn et al., 2016). This evidence concerns the gene NR4A1 and breast cancer.